Sixty patients diagnosed with Stage III–IV H/N carcinoma between 6/93 and 9/94 were treated with SIT-P at 150mg/m 2 weekly ×4 using femoral access to angiographically placed microcatheter into the tumor vascular supply. Concurrent (day 1) daily RT was delivered to the primary tumor and overt nodal disease to 66–74 Gy at 1.8–2.0 Gy/fraction. Fifty-two (87%) of 60 patients completed the chemoradiation therapy protocol. Overall, for both primary/nodal disease, histological/clinical complete response was attained in 45 (79%), and incomplete response in 12 (21%) of 57/60 evaluable patients. The 1.5 year (median follow up=10 months, range 2.5–20) disease control above clavicle is 95% for 57 evaluable patients. Two deaths occurred during treatment. Grade III/IV toxicity has included gastrointestinal in 6, hematologic in 5, mucosal in 12 and neurological in 4 patients. Concurrent RT and SIT-P can be safely delivered with high response rates in unresectable Stage III/IV H/N carcinoma.